Top > Search of International Patents > MARKER FOR PANCREATIC CANCER AND INTRADUCTAL PAPILLARY MUCINOUS TUMORS

MARKER FOR PANCREATIC CANCER AND INTRADUCTAL PAPILLARY MUCINOUS TUMORS

Foreign code F180009327
File No. S2016-0166-C0
Posted date Jan 24, 2018
Country WIPO
International application number 2016JP084537
International publication number WO 2017098915
Date of international filing Nov 22, 2016
Date of international publication Jun 15, 2017
Priority data
  • P2015-242679 (Dec 11, 2015) JP
Title MARKER FOR PANCREATIC CANCER AND INTRADUCTAL PAPILLARY MUCINOUS TUMORS
Abstract The purpose of the present invention is to provide a marker that indicates pancreatic cancer and intraductal papillary mucinous tumors, with high sensitivity and specificity. Furthermore, the purpose of the present invention is also to provide a diagnostic kit for pancreatic cancer and intraductal papillary mucinous tumors, which detects this marker, and a method for evaluating metastatic pancreatic cancer and intraductal papillary mucinous tumors, using the marker. This marker of pancreatic cancer and intraductal papillary mucinous tumors is characterized by including one or more proteins, selected from the group consisting of secretoglobin family-1D member 2, and podocalyxin-like protein. Furthermore, this diagnostic kit for pancreatic cancer and intraductal papillary mucinous tumors is characterized by including an antibody for one or more proteins selected from the group consisting of secretoglobin family-1D member 2, and podocalyxin-like protein.
Outline of related art and contending technology BACKGROUND ART
'Tumor' refers to an abnormally proliferating cell is, the cause of the abnormal proliferation of the lost or removed to a state in which the duration of cell growth. Benign tumors among the tumor is delayed tumor growth, metastasis is not. Therefore, there is no problem if the cut-in general, even if without cutting through the left to stand in a different situation may be said that the life is not. On the other hand, malignant tumor, the cancer is that, unlike benign tumors and rapidly proliferating on, lymph nodes or other organs via the transition and grow. Thus, for example be removed by surgery, or even a slight remaining cancer cells, metastasized lymph nodes or other organs already has been that a cancer cell can initiate proliferation again. Therefore, after the completion of the once treatment of the cancer is poor prognosis and, in that the survival rate 5 years after each cancer investigation, in general, a cancer treatment from 5 was eliminated when a relapse until after more than one year not considered resolved only.
Pancreatic cancer is, most of cancer is called a poor prognosis. As its causes, the pancreas is retroperitoneal organ is difficult to detect early because as well, for pancreatic cancer cell motility is extremely high, for example even cancers equal to or less than 2cm, the surrounding blood vessel, gastrointestinal tract, such as nerve immediately transfers the infiltration and, further, to nearby lymph nodes or metastatic, or distant metastases to the liver and the like. Therefore, evaluate the progression of the cancer is pancreatic cancer is very important.
Biopsy to diagnose cancer accurate, pain to the patient's biopsy. Thus in general, a cancer marker was used a preliminary inspection is performed. Cancer marker, cancer in vivo by specifically substances produced and, in the fluids in the progression of cancer by measuring the amount can be evaluated. Pancreatic cancer markers include for example, about 30 years before cancer cells specifically expressed in abnormal sugar chains of which CA19-9, yet over CA19-9 pancreatic cancer marker is not put to practical use.
However, particularly early in the diagnosis of cancer is pancreatic cancer CA19-9 poor sensitivity, a problem may be less useful. Therefore, a search of a more excellent than that of the cancer marker. Patent Document 1 is for example, cancer is pancreatic cancer specific protein marker is disclosed.
Scope of claims (In Japanese)[請求項1]
セクレトグロビン,ファミリー1D,メンバー2およびポドカリキシン様タンパク質からなる群より選択される1以上のタンパク質を含むことを特徴とする膵がん及び膵管内乳頭粘液性腫瘍のマーカー。
[請求項2]
上記セクレトグロビン,ファミリー1D,メンバー2が、下記の(1)~(3)の何れかのアミノ酸配列を有する請求項1に記載の膵がん及び膵管内乳頭粘液性腫瘍のマーカー。
(1)配列番号1に記載のアミノ酸配列;
(2)配列番号1に記載のアミノ酸配列において1以上、5以下のアミノ酸の欠失、置換および/または付加を有するアミノ酸配列;
(3)配列番号1に記載のアミノ酸配列に対して95%以上の相同性を有するアミノ酸配列。
[請求項3]
上記ポドカリキシン様タンパク質が、下記の(4)~(6)の何れかのアミノ酸配列を有する請求項1または2に記載の膵がん及び膵管内乳頭粘液性腫瘍のマーカー。
(4)配列番号2に記載のアミノ酸配列;
(5)配列番号2に記載のアミノ酸配列において1以上、25以下のアミノ酸の欠失、置換および/または付加を有するアミノ酸配列;
(6)配列番号2に記載のアミノ酸配列に対して95%以上の相同性を有するアミノ酸配列。
[請求項4]
さらに、CA19-9を含む請求項1~3のいずれかに記載の膵がん及び膵管内乳頭粘液性腫瘍のマーカー。
[請求項5]
セクレトグロビン,ファミリー1D,メンバー2およびポドカリキシン様タンパク質からなる群より選択される1以上のタンパク質に対する抗体を含むことを特徴とする膵がん及び膵管内乳頭粘液性腫瘍の診断キット。
[請求項6]
さらに、CA19-9に対する抗体を含む請求項5に記載の膵がん及び膵管内乳頭粘液性腫瘍の診断キット。
[請求項7]
膵がん細胞の転移を評価するための方法であって、
セクレトグロビン,ファミリー1D,メンバー2およびポドカリキシン様タンパク質からなる群より選択される1以上のタンパク質の試料中の濃度を測定する工程を含むことを特徴とする方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KOCHI UNIVERSITY
  • Inventor
  • TANIUCHI, Keisuke
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close